Want to see GB:HEMO full AI Analyst Report?
HemoGenyx Pharmaceuticals Plc (HEMO) AI Stock Analysis
HemoGenyx Pharmaceuticals Plc
(LSE:HEMO)
The overall score is driven primarily by weak financial performance, with no revenue, deep and widening losses, shrinking asset and equity bases, and ongoing negative cash flows indicating high funding and solvency risk. Technicals are moderately supportive, as the price trades above key shorter-term moving averages but momentum appears to be slowing, implying a fragile uptrend rather than robust strength. Valuation is constrained by a negative P/E and no dividend yield, reflecting a speculative profile where investors are relying on future biotech pipeline milestones rather than current fundamentals.
HemoGenyx Pharmaceuticals Plc (HEMO) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 39.04M
- Dividend Yield
- ―
- Average Volume (3M)
- 22.59K
- Price to Earnings (P/E)
- -3.1
- Beta (1Y)
- -0.42
- Revenue Growth
- ―
- EPS Growth
- 18.57%
- Country
- UK
- Employees
- 16
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
HemoGenyx Pharmaceuticals Plc Business Overview & Revenue Model
Company Description
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions...
How the Company Makes Money
Publicly available information in the provided context is insufficient to describe HemoGenyx Pharmaceuticals Plc’s specific, current revenue model and key revenue streams in a factual, detailed way (e.g., whether it earns revenue from product sales,...
HemoGenyx Pharmaceuticals Plc Financial Statement Overview
Summary
Financials reflect a high-risk, pre-revenue biotech profile: no revenue to date, escalating net losses, shrinking assets, eroding equity, and consistently negative operating and free cash flow. Recent leverage reduction and some improvement in cash burn slightly temper but do not offset the overall weak financial footing and funding dependency.
Income Statement
15Very NegativeBalance Sheet
28NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -521.15K | -588.75K | -639.28K | -645.68K | -2.60M | -283.65K |
| EBITDA | -9.13M | -4.07M | -4.71M | -5.73M | -3.42M | -2.39M |
| Net Income | -11.31M | -9.76M | -5.62M | -6.69M | -3.98M | -5.10M |
Balance Sheet | ||||||
| Total Assets | 6.87M | 4.18M | 4.21M | 6.11M | 7.09M | 8.52M |
| Cash, Cash Equivalents and Short-Term Investments | 4.58M | 1.59M | 159.26K | 1.25M | 2.53M | 6.84M |
| Total Debt | 1.85M | 2.00M | 2.62M | 2.95M | 3.42M | 10.15K |
| Total Liabilities | 2.60M | 3.03M | 3.36M | 3.32M | 3.85M | 352.84K |
| Stockholders Equity | 4.33M | 1.20M | 897.51K | 2.82M | 3.28M | 8.19M |
Cash Flow | ||||||
| Free Cash Flow | -1.32M | -3.45M | -4.13M | -6.22M | -3.34M | -3.45M |
| Operating Cash Flow | -1.32M | -3.45M | -4.12M | -6.11M | -2.91M | -2.63M |
| Investing Cash Flow | -271.93K | -6,797 | -24.90K | -31.94K | -420.25K | -938.95K |
| Financing Cash Flow | 7.92M | 4.89M | 3.08M | 4.45M | -110.14K | 8.78M |
HemoGenyx Pharmaceuticals Plc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:HEMO, the sentiment is Negative. The current price of 556.20 is below the 20-day moving average (MA) of 685.42, below the 50-day MA of 577.55, and below the 200-day MA of 755.41, indicating a bearish trend. The MACD of 20.04 indicates Positive momentum. The RSI at 41.13 is Neutral, neither overbought nor oversold. The STOCH value of 32.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:HEMO.
HemoGenyx Pharmaceuticals Plc Peers Comparison
Overall Rating
GB:AREC49.4Neutral
GB:HVO49Neutral- GB:HEMO48Neutral
GB:POLB46Neutral
GB:APTA43Neutral
GB:IMM43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:AREC | 49Neutral | GBP 37.37M | 165.00 | 3.75% | ― | ― | ― |
| GB:HVO | 49Neutral | GBP 41.30M | -3.33 | -35.13% | 3.33% | -24.24% | -329.49% |
| GB:HEMO | 48Neutral | GBP 39.04M | -3.13 | -409.57% | ― | ― | 18.57% |
| GB:POLB | 46Neutral | GBP 49.62M | -8.33 | -71.28% | ― | ― | 31.58% |
| GB:APTA | 43Neutral | GBP 10.23M | -9.83 | -46.61% | ― | 28.35% | 57.14% |
| GB:IMM | 43Neutral | GBP 20.28M | -2.60 | -559.87% | ― | ― | 5.62% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:HEMO | Hemogenyx Pharmaceuticals Plc | 566.00 | -262.00 | -31.64% | |
| GB:IMM | ImmuPharma plc | 3.25 | -7.15 | -68.75% | |
| GB:HVO | Open Orphan Plc | 6.00 | -0.55 | -8.40% | |
| GB:POLB | Poolbeg Pharma Ltd. | 6.50 | 2.65 | 68.83% | |
| GB:AREC | Arecor Therapeutics PLC | 82.50 | 11.00 | 15.38% | |
| GB:APTA | Aptamer Group Plc | 0.29 | -0.51 | -63.13% |
HemoGenyx Pharmaceuticals Plc Corporate Events
Hemogenyx Partners with Nitto to Explore In Vivo Off-the-Shelf CAR-T Delivery
PositiveHemogenyx Pharmaceuticals has entered a feasibility study agreement with Japan-based materials specialist Nitto Denko to test whether Nitto’s cell-targeted lipid nanoparticle technology can deliver Hemogenyx’s FLT3-targeting CAR mRNA to h...
Hemogenyx clarifies total voting rights and share capital
NeutralHemogenyx Pharmaceuticals plc has confirmed that its total issued share capital as of 30 September 2026 stands at 6,896,786 ordinary shares of 1p each, with no shares held in treasury. This means the company currently has 6,896,786 voting rights in i...
Hemogenyx Advances AML CAR-T Trial and Sets Up Early European Commercial Pathways
PositiveHemogenyx Pharmaceuticals reported interim results for the six months to 30 June 2026, highlighting continued progress of its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukaemia. The company’s second annual FDA IND report show...
Hemogenyx Raises £291,665 Through Warrant Exercises Ahead of LSE Admission
PositiveHemogenyx Pharmaceuticals plc has received notices to exercise warrants over 96,825 new ordinary shares, at prices between 180p and 350p, raising £291,665 in fresh capital. The new shares will rank pari passu with existing stock and are expected...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 06, 2026